Emergence of maribavir resistance in an AIDS patient with refractory cytomegalovirus viremia and retinitis (EACS 2025) - Jul 16, 2025 - Abstract #eP.C031; Location: ePoster Exhibition; "Antiretroviral therapy with BIC/FTC/TAF was initiated...Relapsed CMV viremia (2.2 x 10⁵ copies/mL) was detected, despite valganciclovir prophylaxis and a ganciclovir resistance mutation (UL97 L595S) was confirmed. Foscarnet was attempted but discontinued due to nephrotoxicity...Letermovir was used as salvage anti-CMV therapy, the patient died from febrile neutropenia and septic shock due to Pseudomonas aeruginosa bacteremia...To the best of our knowledge, no other cases of genotypic maribavir resistance in treated patients with AIDS have been reported to date. Novel antiviral strategies may be critical in managing resistant CMV in non-transplant, immunocompromised patients."
Clinical • Cytomegalovirus Infection • Human Immunodeficiency Virus • Infectious Disease • Septic Shock • CD4
|
|
V. Sakka 1; M. Mitropoulou 1; M. Evangelidou 2; E. Stravodimou 1; V. Rapti 1; E. Gourdoupari 1; E. Kakalou 1; E. Angelakis 2; P. Mavroudis 1; M. Bei 1; K. Syrigos 1; G. Poulakou 1
|